Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 1982 May;103(2):107–118. doi: 10.1007/BF00409641

Evidence for host resistance in 1,3 bis(2-chloroethyl)-1-nitrosourea treatment induced in syngeneic LSA lymphoma

Y Maruyama 1,✉, A Williams 1, J M Feola 1, C Nava 1
PMCID: PMC12253921  PMID: 7096433

Abstract

The anticancer agent 1,3 Bis(2-chloroethyl)-1-Nitrosourea (BCNU) cures the advanced syngeneic LSA lymphoma of C57BL mice with high efficiency. The cured animals resist further tumor challenge by large numbers of viable syngeneic tumor cells. Growth assays of spleen proliferation of the intravenously inoculated tumor revealed a progressive-regressive pattern of spleen growth after LSA-tumor injection. Lymphoma colony forming units (LCFU) in the spleen initially increased then regressed. In vitro assays of serum showed a alack of cytotoxic activity in mice cured by BCNU. Added spleen, thymus, or bone-marrow cells were similarly ineffective. Spleen and bone-marrow cells from immune mice passively transferred to normal mice showed weak cytotoxic activity against the LSA tumor. BCNU-cured mouse cells were more effective in protection than those cured with Chlorozotocin (CLZ).

Key words: Host resistance, Chemotherapy, Tumor regression, Induced resistance

Footnotes

Supported by research grants nos. RO1 CA 13849, PO1 17786 from the National Cancer Institute, U.S. Public Health Service, U.S. Department of Health, Education and Welfare, Bethesda, Maryland 20014, The University of Kentucky Research Foundation, The Ephraim McDowell Cancer Network, and the Kircher Foundation

References

  1. Axelrad A (1965) Antigenic behavior of lymphoma cell populations in mice as revealed by the spleen colony method. Prog Exp Tumor Res 6:30–83 [DOI] [PubMed] [Google Scholar]
  2. Bonmassar E, Bonmassar A, Vadlamudi, S, Goldin A (1970) Immunological alteration of leukemic cells in vivo after treatment with antitumor drugs. Proc Natl Acad Sci 66:1089–1095 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bonmassar E, Testorelli C, Franco, P, Goldin A, Cudkowicz G (1975) Changes of the immunogenic properties of a radiation-induced mouse lymphoma following treatment with antitumor drugs. Cancer Res 35:1957–1962 [PubMed] [Google Scholar]
  4. Feola JM, Maruyama Y (1979) Host resistance to tumor after cure of advanced lymphoma by treatment with BCNU and Chlorozotocin. Cancer Treat Rep 63:1409–1412 [PubMed] [Google Scholar]
  5. Ferrer JF, Kaplan HS (1968) Antigenic characteristics of lymphomas induced by radiation leukemia virus (RadLV) in mice and rats. Cancer Res 28:2522–2528 [PubMed] [Google Scholar]
  6. Glynn JP, Humphrey SR, Trivers G, Bianco AR, Goldin A (1968) Studies on immunity to leukemia l1210 in mice. Cancer Res 23:1008–1016 [PubMed] [Google Scholar]
  7. Graff RJ, Valeriote F, Medoff G (1975) Marked histoincompatibility between and within sublines of AKR mice used in a syngeneic leukemic model. J Natl Cancer Inst 55:1015–1016 [DOI] [PubMed] [Google Scholar]
  8. Houchens DP, Bonmassar E, Gaston MR, Kende M, Goldin A (1976) Drug mediated immunogenic charges of virus induced leukemia in vivo. Cancer Res 36:1347–1352 [PubMed] [Google Scholar]
  9. Ihle JN, McEwan R, Bengali K (1976) Radiation leukemia in C57BL/6 mice. I. Lack of serological evidence for the role of endogenous ecotropic viruses in pathogenesis. J Exp Med 144:1391–1405 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Johnson EA, Brown BW (1961) The Spearman estimator for serial dilution assay. Biometrics 17:79–88 [Google Scholar]
  11. Kitano M, Mihich E, Pressman D (1972) Antigenic differences between leukemia L1210 and a subline resistant to methylglyoxal-bis(guanylhydrazone). Cancer Res 32:181–186 [PubMed] [Google Scholar]
  12. Lieberman M, Kaplan HS (1959) Leukemogenic activity of filtrates from radiation-induced lymphoid tumors of mice. Science 130:387–389 [DOI] [PubMed] [Google Scholar]
  13. Maruyama Y (1967) Contribution of host resistance to radiosensitivity of an isologous mouse lymphoma cell by non-specific resistance. Int J Rad Biol 12:277–292 [DOI] [PubMed] [Google Scholar]
  14. Maruyama Y (1968) Lethal cell number for mouse lymphoma dosage-response studies: indirect study using intravenous inocula. Int J Cancer 3:788–794 [DOI] [PubMed] [Google Scholar]
  15. Maruyama Y (1969) Recognition of the irradiated, isogenic mouse lymphoma cell. Radiol 92:630–632 [DOI] [PubMed] [Google Scholar]
  16. Maruyama Y (1971) Host resistance and radiation response of syngeneic mouse lymphoma cells. J Natl Cancer Inst 46:963–971 [PubMed] [Google Scholar]
  17. Maruyama Y (1976) Study of host immunological resistance to syngeneic lymphoma using whole body irradiation. Int J Radiat Oncol Biol Phys 1:1159–1169 [DOI] [PubMed] [Google Scholar]
  18. Maruyama Y, Ackerman E, Khan FM (1969) Inactivation of an X-irradiated tumor by independent processes in vivo. Int J Cancer 4:793–798 [DOI] [PubMed] [Google Scholar]
  19. Maruyama Y, Brown BW (1964) The growth of murine lymphomatous tumor cells as determined by host survival time. Int J Radiol Biol 8:59–73 [DOI] [PubMed] [Google Scholar]
  20. Maruyama Y, Feola JM (1973) Active host-resistance for transplant syngeneic C57BL lymphomas: Comparison of recently adapted and long transplanted tumors. Oncology 28:52–62 [DOI] [PubMed] [Google Scholar]
  21. Maruyama Y, Feola J (1969) 1,3 Bis(2-chloroethyl)-1-nitrosouera-induced host resistance to syngeneic mouse leukemias. Leukemia Res 4:417–415 [DOI] [PubMed] [Google Scholar]
  22. Maruyama Y, Johnson EA (1969) Quantiative study of isologous tumor cell inactivation and effective cell fraction for the LSA mouse lymphoma. Cancer 23:309–312 [DOI] [PubMed] [Google Scholar]
  23. Maruyama Y, Lee TC (1980) Growth, of LSA lymphoma in solid organs: demonstration of multiphasic growth. Cancer Biochem Biophys 4:257–263 [PubMed] [Google Scholar]
  24. Medoff G, Valeriote F, Ryan J, Tolen S (1977) Response of transplanted AKR leukemia to combination therapy with amphotericin B and 1,3 bis(2-chloroethyl)-1-nitrosouera: Dose and schedude dependency. J Natl Cancer Inst 58:949–953 [DOI] [PubMed] [Google Scholar]
  25. Mihich E (1969) Combined effects of chemotherapy and immunity against leukemia L1210 in DBA/2 mice. Cancer Res 29:848–854 [PubMed] [Google Scholar]
  26. Mihich E, Kitano M (1979) Differences in the immunogenicity of leukemia L1210 sublines in DBA/2 mice. Cancer Res 31:1999–2003 [PubMed] [Google Scholar]
  27. Nicolin A, Bini A, Franco P, Goldin A (1979) Cell mediated response to a mouse leukemic subline antigenically altered following drug treatment in vivo. Cancer Chemother Rep 58:325–330 [PubMed] [Google Scholar]
  28. Peters RL, Sass B, Stephenson JR, Al-Ghazzouli IK, Hino S, Donahue RM, Kende M, Aaronson SA, Kelloff GJ (1977) Immunoprevention of X-ray-induced leukemias in the C57BL mouse. Proc Natl Acad Sci 74:1697–1701 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Revesz L (1960) Detection of antigenic differences in isologous host-tumor systems by pretreatment with heavily irradiated tumor cells. Cancer Res 20:443–451 [Google Scholar]
  30. Schabel FM Jr, Skipper HE, Laster WR Jr, Trader MW, Thompson SA (1966) Experimental evaluation of potential anticancer agents. XX. Development of immunity to leukemia L1210 in BDF1 mice and effects of therapy. Cancer Chemother Rep 50:55–77 [PubMed] [Google Scholar]
  31. Silini G, Maruyama Y (1965) Studies of the LSA ascites lymphoma of C57BL mice. I. Transplantation characteristics and radiosensitivity of cells during serial passage. J Natl Cancer Inst 35:841–849 [PubMed] [Google Scholar]
  32. Slettenmark B, Klein E (1962) Cytotoxic and neutralization tests with sera and lymph node cells of isologous mice with induced resistance to gross lymphomas. Cancer Res 22:947–961 [PubMed] [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES